Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia

International Journal of Antimicrobial Agents
Thana KhawcharoenpornPimsiri Tiamsak

Abstract

Data on treatment regimens and outcomes of extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) pneumonia are currently limited. A 6-year retrospective cohort study of adult patients diagnosed with XDR-PA pneumonia was conducted between January 2011 and December 2016. All XDR-PA isolates were susceptible to colistin and/or fosfomycin alone. Some XDR-PA isolates, which had minimum inhibitory concentrations for doripenem of 4 or 8 mg/L, were considered to be susceptible to 4-h prolonged infusion therapy with high-dose doripenem. Definite treatment regimens were categorized into three groups: inactive therapy, active monotherapy and active combined two-drug therapy. Outcomes were compared between the three groups. In total, 136 patients were included, and 37% had ventilator-associated pneumonia. Twenty-two, 74 and 40 patients received inactive therapy, active monotherapy and active combined two-drug therapy, respectively. Demographic and clinical characteristics were comparable between the three groups. Rates of 28-day survival and microbiological cure were significantly higher in patients who received active combined two-drug therapy compared with those who received active monotherapy and inactive therapy [90% vs 51% vs 0% ...Continue Reading

Citations

Jan 23, 2019·Expert Review of Anti-infective Therapy·George DimopoulosGaryphalia Poulakou
Oct 1, 2019·Current Opinion in Infectious Diseases·Matteo BassettiDaniele Roberto Giacobbe
Nov 21, 2019·Protein Science : a Publication of the Protein Society·Jed F Fisher, Shahriar Mobashery
Feb 26, 2020·British Journal of Hospital Medicine·Joshua A YorkGavin Barlow
Oct 31, 2020·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Sanjida JahanGeorge A Pankey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.